O	0	5	Phase
O	6	9	III
O	10	15	study
O	16	25	comparing
B-intervention	26	36	exemestane
O	37	41	with
B-control	42	51	tamoxifen
O	52	54	as
O	55	60	first
O	60	61	-
O	61	65	line
O	66	74	hormonal
O	75	84	treatment
O	85	87	of
O	88	98	metastatic
O	99	105	breast
O	106	112	cancer
O	113	115	in
O	116	130	postmenopausal
O	131	136	women
O	136	137	:
O	138	141	the
O	142	150	European
O	151	163	Organisation
O	164	167	for
O	168	176	Research
O	177	180	and
O	181	190	Treatment
O	191	193	of
O	194	200	Cancer
O	201	207	Breast
O	208	214	Cancer
O	215	226	Cooperative
O	227	232	Group
O	232	233	.

O	234	238	This
O	239	244	phase
O	245	248	III
O	249	259	randomized
O	260	264	open
O	264	265	-
O	265	270	label
O	271	279	clinical
O	280	285	trial
O	286	289	was
O	290	298	designed
O	299	301	to
O	302	310	evaluate
O	311	314	the
O	315	323	efficacy
O	324	327	and
O	328	334	safety
O	335	337	of
O	338	341	the
O	342	351	steroidal
O	352	361	aromatase
O	362	373	inactivator
O	374	384	exemestane
O	385	391	versus
O	392	395	the
O	396	408	antiestrogen
O	409	418	tamoxifen
O	419	421	as
O	422	427	first
O	427	428	-
O	428	432	line
O	433	442	treatment
O	443	446	for
O	447	457	metastatic
O	458	464	breast
O	465	471	cancer
O	472	473	(
O	473	476	MBC
O	476	477	)
O	478	480	in
O	481	495	postmenopausal
O	496	501	women
O	501	502	.

O	503	506	The
O	507	512	study
O	513	516	was
O	517	526	conducted
O	527	529	at
O	530	532	81
O	533	540	centers
O	541	544	and
O	545	553	enrolled
B-eligibility	554	568	postmenopausal
I-eligibility	569	577	patients
I-eligibility	578	582	with
I-eligibility	583	593	measurable
I-eligibility	594	601	hormone
I-eligibility	601	602	-
I-eligibility	602	611	sensitive
I-eligibility	612	622	metastatic
I-eligibility	623	625	or
I-eligibility	626	633	locally
I-eligibility	634	642	advanced
I-eligibility	643	649	breast
I-eligibility	650	656	cancer
O	656	657	.

O	658	663	Prior
O	664	672	adjuvant
O	673	685	chemotherapy
O	686	689	and
O	689	690	/
O	690	692	or
O	693	702	tamoxifen
O	703	707	were
O	708	715	allowed
O	715	716	.

O	717	720	One
O	721	729	previous
O	730	742	chemotherapy
O	743	750	regimen
O	751	754	and
O	755	757	no
O	758	763	prior
O	764	771	hormone
O	772	779	therapy
O	780	783	for
O	784	792	advanced
O	793	800	disease
O	801	805	were
O	806	815	permitted
O	815	816	.

O	817	825	Patients
O	826	830	were
O	831	839	randomly
O	840	848	assigned
O	849	851	to
O	852	859	receive
O	860	870	exemestane
O	871	873	25
O	874	876	mg
O	877	879	or
O	880	889	tamoxifen
O	890	892	20
O	893	895	mg
O	896	902	orally
O	903	907	once
O	908	913	daily
O	914	919	until
O	920	927	disease
O	928	939	progression
O	940	942	or
O	943	955	unacceptable
O	956	964	toxicity
O	965	973	occurred
O	973	974	.

O	975	976	A
O	977	982	total
O	983	985	of
B-total-participants	986	989	371
O	990	998	patients
O	999	1007	enrolled
O	1008	1010	at
O	1011	1013	79
O	1014	1019	sites
O	1020	1021	(
B-intervention-participants	1021	1024	182
O	1025	1035	exemestane
O	1035	1036	,
B-control-participants	1037	1040	189
O	1041	1050	tamoxifen
O	1050	1051	)
O	1052	1056	were
O	1057	1065	included
O	1066	1068	in
O	1069	1072	the
O	1073	1081	analysis
O	1081	1082	.

O	1083	1087	Both
O	1088	1098	treatments
O	1099	1103	were
O	1104	1113	generally
O	1114	1118	well
O	1119	1128	tolerated
O	1129	1136	without
O	1137	1142	major
O	1143	1151	toxicity
O	1151	1152	.

B-outcome	1153	1160	Overall
I-outcome	1161	1169	response
I-outcome	1170	1174	rate
O	1175	1178	was
O	1179	1186	greater
O	1187	1190	for
O	1191	1201	exemestane
O	1202	1206	than
O	1207	1210	for
O	1211	1220	tamoxifen
O	1221	1230	treatment
O	1231	1232	(
B-iv-bin-percent	1232	1234	46
I-iv-bin-percent	1234	1235	%
O	1236	1237	v
B-cv-bin-percent	1238	1240	31
I-cv-bin-percent	1240	1241	%
O	1241	1242	;
O	1243	1247	odds
O	1248	1253	ratio
O	1254	1255	=
O	1256	1257	1
O	1257	1258	.
O	1258	1260	85
O	1260	1261	;
O	1262	1264	95
O	1264	1265	%
O	1266	1268	CI
O	1268	1269	,
O	1270	1271	1
O	1271	1272	.
O	1272	1274	21
O	1275	1277	to
O	1278	1279	2
O	1279	1280	.
O	1280	1282	82
O	1282	1283	;
O	1284	1285	P
O	1286	1287	=
O	1288	1289	.
O	1289	1292	005
O	1292	1293	)
O	1293	1294	.

B-outcome	1295	1301	Median
I-outcome	1302	1313	progression
I-outcome	1313	1314	-
I-outcome	1314	1318	free
I-outcome	1319	1327	survival
I-outcome	1328	1329	(
I-outcome	1329	1332	PFS
I-outcome	1332	1333	)
O	1334	1337	was
O	1338	1344	longer
O	1345	1349	with
O	1350	1360	exemestane
O	1361	1362	(
B-cv-cont-median	1362	1363	9
I-cv-cont-median	1363	1364	.
I-cv-cont-median	1364	1365	9
I-cv-cont-median	1366	1372	months
O	1372	1373	;
O	1374	1376	95
O	1376	1377	%
O	1378	1380	CI
O	1380	1381	,
O	1382	1383	8
O	1383	1384	.
O	1384	1385	7
O	1386	1388	to
O	1389	1391	11
O	1391	1392	.
O	1392	1393	8
O	1394	1400	months
O	1400	1401	)
O	1402	1406	than
O	1407	1411	with
O	1412	1421	tamoxifen
O	1422	1423	(
B-iv-cont-median	1423	1424	5
I-iv-cont-median	1424	1425	.
I-iv-cont-median	1425	1426	8
I-iv-cont-median	1427	1433	months
O	1433	1434	;
O	1435	1437	95
O	1437	1438	%
O	1439	1441	CI
O	1441	1442	,
O	1443	1444	5
O	1444	1445	.
O	1445	1446	3
O	1447	1449	to
O	1450	1451	8
O	1451	1452	.
O	1452	1453	1
O	1454	1460	months
O	1460	1461	)
O	1461	1462	.

O	1463	1470	However
O	1470	1471	,
O	1472	1477	these
O	1478	1483	early
O	1484	1495	differences
O	1496	1497	(
O	1497	1505	Wilcoxon
O	1506	1507	P
O	1508	1509	=
O	1510	1511	.
O	1511	1514	028
O	1514	1515	)
O	1516	1519	did
O	1520	1523	not
O	1524	1533	translate
O	1534	1536	to
O	1537	1538	a
O	1539	1545	longer
O	1545	1546	-
O	1546	1550	term
O	1551	1558	benefit
O	1559	1561	in
B-outcome-Measure	1562	1565	PFS
O	1565	1566	,
O	1567	1570	the
O	1571	1578	primary
O	1579	1584	study
O	1585	1588	end
O	1589	1594	point
O	1595	1596	(
O	1596	1599	log
O	1599	1600	-
O	1600	1604	rank
O	1605	1606	P
O	1607	1608	=
O	1609	1610	.
O	1610	1613	121
O	1613	1614	)
O	1614	1615	.

O	1616	1621	There
O	1622	1625	was
O	1626	1630	also
O	1631	1633	no
O	1634	1644	difference
O	1645	1647	in
B-outcome	1648	1656	survival
O	1657	1664	between
O	1665	1669	both
O	1670	1675	study
O	1676	1680	arms
O	1680	1681	.

O	1682	1692	Exemestane
O	1693	1695	is
O	1696	1698	an
O	1699	1708	effective
O	1709	1712	and
O	1713	1717	well
O	1717	1718	-
O	1718	1727	tolerated
O	1728	1733	first
O	1733	1734	-
O	1734	1738	line
O	1739	1747	hormonal
O	1748	1757	treatment
O	1758	1761	for
O	1762	1776	postmenopausal
O	1777	1782	women
O	1783	1787	with
O	1788	1791	MBC
O	1792	1795	and
O	1796	1802	offers
O	1803	1814	significant
O	1815	1820	early
O	1821	1832	improvement
O	1833	1835	in
O	1836	1840	time
O	1841	1843	to
O	1844	1849	tumor
O	1850	1861	progression
O	1862	1866	when
O	1867	1875	compared
O	1876	1880	with
O	1881	1890	tamoxifen
O	1890	1891	.
